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Abstract
Background: Various endocrine disorders have been reported in women of
reproductive age, 10% of which is affected by polycystic ovary syndrome (PCOS).
Objective: This study aimed to evaluate the correlation of anti-Müllerian hormone
(AMH) levels with the metabolic syndrome in patients with PCOS.
Materials and Methods: This cross-sectional study employed a consecutive sampling
method using medical records from January 2013 to December 2017 at Dr. Cipto
Mangunkusumo General Hospital polyclinic and Yasmin in vitro fertilization Clinic
(Kencana), Jakarta, Indonesia. The primary outcome of the study was the AMH
levels as independent variable correlated with metabolic syndrome. The secondary
outcome was also the AMH levels correlated with each PCOS phenotype. The
tertiary outcome was each PCOS phenotype as independent variable correlated with
metabolic syndrome.
Results: Women with phenotype 1 of PCOS had a median AMH level of 13.92 (range:
3.88-34.06) ng/ml. 21% patients hadmetabolic syndrome, with amedian AMH level 7.65
(3.77-20.20) ng/ml, higher than the women without metabolic syndrome (p = 0.38). The
most frequent phenotype in women with PCOS was phenotype 4, oligo- or anovulation
and polycystic ovary morphology (OA/PCOM) in 41.3%. The most frequent phenotype
in womenwith metabolic syndromewas phenotype 1, OA + PCOM + hyperandrogenism
in 56.5%.
Conclusion: All PCOS phenotypes exhibited significant correlations with the AMH
level. Phenotype 1 (OA + PCOM + hyperandrogenism) was associated with the highest
AMH level and was significantly associated with metabolic syndrome.
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1. Introduction
Various endocrine disorders have been reported
in women of reproductive age; approximately
10% of them have been reported to be affected
by polycystic ovary syndrome (PCOS) (1, 2).
According to the 2003 Rotterdam consensus,
PCOS is diagnosed by the presence of 2 of
the following 3 criteria: oligo- and/or anovulation
(OA); hyperandrogenism (HA), which is defined
as hirsutism (Ferriman-Gallwey score (FG index)
> 5); and the identification of polycystic ovary
morphology (PCOM) on an ultrasound examination,
defined as a minimum of 12 follicles with diameters
of 2-9 mm per ovary and/or an increased ovarian
volume (minimum: 10mm3). Based on these criteria,
patients with PCOS can be subdivided into four
phenotypic groups: phenotype 1, OA + HA + PCOM;
phenotype-2, OA + HA; phenotype-3, PCOM + HA;
and phenotype-4, OA + PCOM (3-5).
“The Modified National Cholesterol Education
Program Adult Treatment Panel (NCEP ATP III)
defined metabolic syndrome as the presence
of three of the following five criteria: waist
circumference of > 80 cm, blood pressure of >
130/85 mmHg, fasting triglyceride (TG) level of >
150 mg/dl, fasting high-density lipoprotein (HDL)
cholesterol level of < 50 mg/dl, and fasting blood
sugar of > 100 mg/dl” (6, 7).
Follicle development is regulated by anti-
Müllerian hormone (AMH), also known as
transforming growth factor (TGF)-β. This hormone
inhibits primordial follicle growth by decreasing
the sensitivity of the follicles to follicle-stimulating
hormone (FSH), resulting in the pooling of small
antral follicles (8). Because AMH regulates follicle
growth, it is considered to be a marker of ovarian
reserve. A higher level of plasma AMH indicates
the severity of PCOS (9).
Our study aimed to evaluate the correlation
of anti-Müllerian hormone (AMH) levels with the
metabolic syndrome in patients with PCOS.
2. Materials and Methods
In this cross-sectional study, medical records
of 109 PCOs women with available AMH data
referred to Dr. Cipto Mangunkusumo General
Hospital (RSCM) polyclinic and Yasmin in vitro
fertilization Clinic (Kencana), Jakarta, Indonesia
from January 2013 to December 2017 were
investigated. Data collection was performed using
consecutive sampling method. The inclusion
criteria were women in reproductive age (15-45
years) and the presence of the Rotterdam criteria
for PCOS and NCEP ATP III criteria for metabolic
syndrome. Participants were classified by PCOS
phenotypes into 4 groups. Information on the
levels of AMH, BMI, waist circumference, blood
pressure, trygliceride, HDL, Ferrimen-Galwey
(FG)-index, hypertension, diabetes mellitus (DM),
and metabolic syndrome were extracted from
participants’ record and recorded. The primary
outcome of the study was the AMH levels as
independent variable correlated with metabolic
syndrome. The secondary outcome was also the
AMH levels correlated with each PCOS phenotype.
The tertiary outcome was each PCOS phenotype
as independent variable correlated with metabolic
syndrome.
2.1. Ethical consideration
This study was approved by the Ethics
Committee of the Faculty of Medicine (reference
number: 30/UN2.F1/ETIK/2015). Informed consent
was obtained from every participant prior to study
enrollment.
2.2. Statistical analysis
Statistical analyses were done using SPSS,
version 22 (Statistical Package for the Social
Sciences, version 22.0, SPSS Inc, Chicago,
Illinois, USA) . Abnormally distributed data
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are presented as medians (ranges) and were
analyzed statistically using the Mann-Whitney
test, independent t test, Chi-square test,
and Fisher’s exact test. Additionally, 95%
confidence intervals (CI) were calculated for
the study data and p < 0.05 to be statistically
significant.
3. Results
The study samples included 109 PCOs women
with available AMH data. According to our
results, phenotype-1 was the most frequent
PCOS phenotype in women with metabolic
syndrome (56.5%), whereas phenotype-4 was
most frequent in women without metabolic
syndrome (43.1%) (Table I). As shown in Table II,
the PCOS phenotype-1 group had the highest
frequency of metabolic syndrome (36.1%),
and the highest AMH level, 12.99 (3.88-
34.06) ng/ml. The phenotype-3 group had the
highest FG index (7), while the phenotype-
4 group had the highest frequencies of DM.
Further, the phenotype-1 group had the highest
frequencies of hypertension. An independent t
test revealed significant differences in the AMH
levels between the different PCOS phenotypes.
Phenotype-1 was the most frequent and the most
associated with the highest AMH level (Table
III).
AMann-Whitney test was then applied to test the
association between the AMH level and metabolic
syndrome status. Notably, 21% of participants
had metabolic syndrome, with a median AMH
level of 7.65 (3.77-20.20) ng/ml compared to
79% of participants without metabolic syndrome
who had a median AMH level of 7.05 (3.11-
34.06) ng/ml. Although, these differences was
not significant (p > 0.05). A linear regression
analysis revealed significant correlations of age
and HDL with the AMH level as a predictor of
metabolic syndrome with p = 0.004 and p =
0.034, respectively. In this analysis, each one-
year increase in age would decrease the AMH
level by 0.58-fold. Each 1 mg/dL increase in the
HDL level would increase the AMH level by 0.19
fold. As shown in table IV, a significant correlation
was observed between PCOS phenotype-1 and
metabolic syndrome (p = 0.007. The highest
frequency of metabolic syndrome, 36.1%, was
observed in the group of patients with phenotype-
1.
Table I. Baseline characteristics of study participants
Characteristic With metabolic syndrome median
(range)
Without metabolic syndrome median
(range)
Age, years 30 (19-41) 32 (18-44)
BMI, kg/m2 28.89 (21.90-38.86) 26.34 (17.40-44.33)
Waist circumference, cm 86.0 (79.0-103.0) 82.5 (57.0-114.0)
Systole, mmHg 127 (102-150) 111 (93-135)
Diastole, mmHg 83 (70-100) 73 (60-94)
Fasting blood glucose, mg/dL 96 (68-271) 86 (68-132)
Triglyceride, mg/dL 169 (83-473) 95 (41-156)
HDL, mg/dL 40 (21-51) 48 (26-64)
FG Index
< 5 4 (36.4%) 7 (63.6%)
≥ 5 14 (22.6%) 48 (77.4%)
PCOs phenotype
1: OA + HA + PCOM 13 (56.5%) 23 (26.7%)
2: OA + HA 1 (4.4%) 11 (12.8%)
3: PCOM + HA 1 (4.4%) 15 (17.4%)
4: OA + PCOM 8 (34.7%) 37 (43.1%)
BMI: Bodymass index; HDL: High-density lipoprotein; FG: Ferriman-Gallwey; OA: Oligo- or anovulation; HA: Hyperandrogenism;
PCOM: Polycystic ovary morphology
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Table II. Baseline characteristics by PCOS phenotype and metabolic syndrome status
Characteristic PCOS phenotype
Phenotype-1 Phenotype-2 Phenotype-3 Phenotype-4
Age, years 30 (18-44) 32 (27-37) 34 (26-40) 32 (20-41)
BMI, kg/m2 27.60 (17.40-38.20) 26.23 (20-36) 22.85 (19.50-40.52) 27.40 (20.20-44.33)
Waist circumference, cm 88 (62-107) 82 (58-105) 66.5 (57-100) 84 (61-114)
Systolic blood pressure, mmHg 120 (93-142) 116.5 (110-140) 110 (100-135) 111 (94-150)
Diastolic blood pressure, mmHg 78 (64-94) 80 (70-90) 80 (69-90) 74 (60-100)
Fasting blood glucose, mg/dL 88 (68-126) 87.5 (68-110) 86 (82-132) 86 (72-271)
Triglyceride, mg/dL 109 (45-473) 117 (72-169) 156 (90-174) 95.5 (41-422)
HDL, mg/DL 41 (21-53) 48 (42-62) 44 (37-49) 51 (32-64)
Metabolic syndrome 13 (36.1%) 1 (8.3 %) 1 (6.2%) 8 (17.8%)
FG index 6 (1-14) 6 (4-8) 7 (1-14) 2.5 (0-4)
Hypertension 5 (13.9%) 1 (8.3 %) 1 (6.2%) 5 (11.1%)
DM 5 (14.3%) 1 (8.3%) 2 (12,5%) 8 (20%)
AMH, ng/ml 12.99 (3.88-34.06) 4.05 (3.11-15) 4.98 (4.05-8.60) 6.49 (3.7-18.9)
*BMI: Body mass index; HDL: High-density lipoprotein; AMH: Anti-Müllerian hormone; FG: Ferriman-Gallwey; DM: Diabetes
mellitus; PCOS: Polycystic ovary syndrome
Table III. Correlations of AMH levels with polycystic ovary syndrome phenotypes
n (%) AMH [median (min-max)] P-value
Phenotype 1: OA + HA + PCOM 36 (33) 13.92 (3.88-34.06) <0.001
Phenotype 2: OA + HA 12 (11) 4.05 (3.11-15.0) 0.004
Phenotype 3: PCOM + HA 16 (14.7) 4.70 (4.05-8.60) 0.005
Phenotype 4: OA + PCOM 45 (41.3) 6.49 (3.70-17.59) 0.023
*AMH: Anti-Müllerianhormone; OA: Oligo-or anovulation; HA: Hyperandrogenism; PCOM: Polycystic ovary morphology
**Independent t test
Table IV. Correlations of PCOS phenotypes with metabolic syndrome
Variables Metabolic syndromes P-value OR 95% CI
Yes No Min Max
n % n %
Phenotype 1: PCOM + Anovulation + Hyperandrogenism 13 36.1 23 63.9 0.007* 3.56 0.10 9.23
Phenotype 2: Anovulation + Hyperandrogenism 1 8.3 11 91.7 0.454# 0.31 0.04 2.54
Phenotype 3: PCOM + Hyperandrogenism 1 6.2 15 93.8 0.184# 0.22 0.03 1.72
Phenotype 4: PCOM + Anovulation 8 17.8 37 82.2 0.476* 0.71 0.27 1.84
Total 23 21.10 86 78.90
*Chi-square test; #Fisher’s exact test
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4. Discussion
In this study, 23% of women with PCOS had
metabolic syndrome, compared to reported rates
of 8.2%, 14.5%, 30.6%, and 46% from studies
performed in Italy, Korea, South India, and the
USA, respectively (4, 10-12). These inter-study
differences may be attributable to differences in
lifestyles, diets, and the criteria used to define
metabolic syndrome. Moreover, we observed a
median AMH level of 7.65 ng/ml in women
with metabolic syndrome, which did not differ
significantly from the level of 7.05 ng/ml in
those without metabolic syndrome (p = 0.387).
This observation is consistent with the findings
from previous studies by Wiweko and colleagues
and Lin and colleagues which non-significantly
higher levels of AMH were observed in women
with metabolic syndrome. Interestingly, in women,
PCOS has been associated with dyslipidemia, as
the high level of androgens increases the risk
of atherosclerosis. AMH levels have also been
observed to correlate with markers of metabolic
syndrome, such as the HDL and triglyceride levels
(11, 12).
In our study, more than half of the women with
PCOS phenotype-1 were found to have metabolic
syndrome. Accordingly, this was considered the
group most likely to present with metabolic
syndrome. Our finding was similar to that of a study
conducted in Poland by Gluszak and colleagues,
who reported phenotype 1 as the most frequent
(60.1%). Numerous other studies have also reported
that phenotype-1 was the most prevalent and was
associated with insulin resistance (8, 9, 13-14).
The highest median AMH levels were also
observed in women with PCOS phenotype-1 (13.92
ng/ml), and this level was significantly higher than
the levels observed in other phenotype groups (p
< 0.01). Normally, the preantral follicle and small
antral follicle are the greatest producers of AMH.
However, once the follicle diameter exceeds 8
mm, AMH production is reduced and the follicular
sensitivity to FSH increases. However, AMH levels
75 times greater than normal were observed
in the granulosa cell masses of patients with
PCOS, and this phenomenon may be a potential
contributor to anovulation. Still, the underlying
cause of increased AMH production remains
unknown, although several other signals produced
by granulosa cells and oocytes may modulate the
ovarian environment and affect oocyte maturation
(8).
In our study, we found that metabolic syndrome
is most common among women with PCOS
phenotype-1, followed by phenotypes-4, 2,
and 3. These results differ from those of
previous studies that observed the occurrence
of metabolic syndrome in association with many
hyperandrogenic conditions (15, 16). Similarly,
normoandrogenic PCOS was associated with
relatively lower risks of metabolic syndrome,
cardiovascular risk factors, and insulin sensitivity
when compared with hyperandrogenic PCOS
(7). Furthermore, our phenotypic analyses
revealed that women with metabolic syndrome
mostly presented with PCOS phenotypes 1
(36%) and 4 (17.8%), and both phenotypes were
associated with relatively larger median waist
circumferences (94 and 85 cm, respectively)
when compared to those of patients with
phenotypes-2 and 3. Intra-abdominal fat is
the greatest contributor to the turnover of
free fatty acids derived from brown adipose
tissue and subsequent distribution to other
body organs. Intra-abdominal fat also secretes
adipocytokines, such as leptin, adiponectin,
resistin, and interleukins (IL-1 and IL-6), which act
as energy regulators and inflammatory markers
and are thus correlated strongly with metabolic
syndrome (17).
We further identified a statistically significant
association between increased AMH levels and
metabolic syndrome (p = 0.03). The observed
inverse relationship between age and AMH levels
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reflects how the ability of a woman to produce
oocytes of good quality and quantity decreases
with age. Our multiple linear regression further
identified statistically significant relationships of
age with the AMH and HDL concentrations. The
observed linear relationship between AMH and
HDL is consistent with the findings of a study by
Yarde and colleagues, who reported that increases
in HDL-C up to 1.6 mmol/L were associated with
increases in AMH to 3.0 ng/ml (18).
5. Conclusion
In summary, AMH can be used as a marker for
metabolic syndrome, especially in phenotype 1 as
it was associated with insulin resistance. Further
research with a better research design is needed
to enhance our results.
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